Related Experiment Videos
Percutaneous transluminal septal reduction for hypertrophic obstructive cardiomyopathy: report from an international
Hope E Buell1, Rodney H Stables, Elizabeth R DeLong
1The Outcomes Research and Assessment Group, Duke Clinical Research Institute, Durham, North Carolina, USA.
Insights
Treating hypertrophic obstructive cardiomyopathy (HOCM) with percutaneous transluminal septal myocardial ablation (PTSMA) showed variations across international centers. Patient characteristics and treatment details differed significantly between locations, impacting rare disease research.
Area of Science:
- Cardiology
- Rare Diseases
- Medical Interventions
Background:
- Assessing rare disease treatments is difficult due to small patient numbers per center.
- Hypertrophic obstructive cardiomyopathy (HOCM) is a rare condition requiring effective treatment strategies.
Purpose of the Study:
- To evaluate the effectiveness of percutaneous transluminal septal myocardial ablation (PTSMA) for HOCM.
- To identify variations in patient characteristics and treatment protocols across international centers.
Main Methods:
- A multi-center registry was established for patients undergoing PTSMA for HOCM.
- Standardized data definitions were used for clinical severity, prior treatments, and outcomes.
- Patient data was collected via a shared, web-based registry system.
Main Results:
- 51 patients were enrolled, with 47 undergoing the PTSMA procedure.
- Significant inter-center differences were observed in patient demographics (age, gender, family history).
- Variations were noted in symptom severity, diagnostic techniques, and PTSMA procedural details (alcohol amount, injection timing, branches targeted).
Conclusions:
- Despite HOCM being a single disease, significant heterogeneity exists in patient presentation and treatment approaches across international centers.
- This variability highlights challenges in rare disease research and the need for standardized protocols.
Abstract:
Assessing the effectiveness of newer treatments for rare diseases can be challenging because of the small number of patients treated at individual centers. We enrolled patients undergoing percutaneous transluminal septal myocardial ablation (PTSMA) for hypertrophic obstructive cardiomyopathy (HOCM) at five international centers (1 Japan, 2 United Kingdom, and 2 United States). Our study group developed standard data definitions regarding clinical symptom severity, previous HOCM treatment, procedure status, and outcome, and entered patient data directly into a shared, web-based registry system. In the first 10 months of 1998, 51 patients were enrolled in our registry, with 47 ultimately receiving the PTSMA procedure. Although HOCM is consider a single disease, there were significant differences among centers in patient characteristics (age, gender, and family history of HOCM), symptom severity, diagnostic techniques (measurements taken after provocation), and treatment (amount of alcohol used, timing of injection, and number of branches attempted).